Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee backs approval of Uptravi for PAH

Feb. 1, 2016

EMA accepts cabozantinib MAA for review

Feb. 1, 2016

Elotuzumab receives positive CHMP opinion for the treatment of multiple myeloma

Feb. 1, 2016

FDA accepts BLA for bezlotoxumab

Jan. 28, 2016

EMA grants orphan drug status for entolimod as a radiation countermeasure

Jan. 22, 2016

EMA grants orphan drug designation to ARC-AAT

Jan. 20, 2016

EMA approves Samsung Bioepis's biosimilar etanercept Benepali

Jan. 18, 2016

EMA grants orphan drug designation to LOXO-101 for treatment of soft tissue sarcoma

Jan. 18, 2016

Exelixis files MAA for cabozantinib in RCC

Jan. 12, 2016

EMA will review Trevyent under centralized authorization procedure

Jan. 8, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.